CCL3 and chronic obstructive pulmonary disease: On the other hand, the reduced inflammatory response by fluticasone plus ACs through reducing TNF-α, CCL3, and CCL5 can increase the risk for community-acquired pneumonia (CAP) in COPD patients.110